BOSTON, Aug. 18 /PRNewswire/ -- China PharmaHub Corp. ("PharmaHub"), recently merged with World Wide Relics (OTC Bulletin Board: WRLC), which will be shortly changing its name to China PharmaHub Corp, is proud to announce it has signed a cooperation agreement with Chengdu Yongkon Pharmacy Co. Ltd., ("Yongkon"), a pharmaceutical company based in Sichuan, with an established sales network of over 2600 hospitals in China. PharmaHub was authorized by Yongkon as its appointed agent to identify pharmaceutical products and medical devices in the U.S. and negotiate the terms to obtain the rights to sell such products and devices in China.
Yongkon is an established and GMP certified pharmaceutical company with focus on the identification, development, manufacture, sales and distribution of Chinese traditional medicine, biopharmaceuticals and medical equipment with its focus on antiviral drugs, bio-engineering drugs and anticancer drugs. Yongkon manufactures and sells over 90 GMP approved drugs in China. Its leading product, Xiaojinwan, is a well known Traditional Chinese Medicine treating breast hyperplasia, thyroid and benign tumor. Yongkon has a marketing force of over 400 sales personnel in 34 sales offices in over 31 provinces and cities as well as in Beijing, Tianjin, Shanghai and Chongqing.
Richard Lui, CEO of PharmaHub, said "We are glad to gain another capable strategic partner in China. In less than one year of founding, we have successfully established partnerships with Research Institute and Government Agencies in China. We have now taken an important step in the partnership with entrepreneurs. With the accomplishment of this major milestone, we've successfully created a chain of command in the commercialization of technologies we identify and bring to China. Yongkon supports our structure with an established sales and marketing t